Assessing the pharmacokinetics of biologics presents several analytical challenges, from the use of critical reagents and assay sensitivity requirements to regulatory and throughput considerations. In this insight brief, we’ll look at all of those and more in the context of combining immunoassays and LC-MS assays into a hybrid platform. The future possibilities that new frontiers in quantitative analysis of biologics may bring are also discussed.

Authors:
Barry Jones, Ph.D., Director, LC-MS Biologics
Adriane Spytko, Associate Director, LC-MS Biologics

Complete the form below to access this insight brief